Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole versus omeprazole for gastroesophageal reflux disease
PACTR202305577953836Phase 4Completed
- Sponsor
- Sun Pharma
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rabeprazole and omeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Sun Pharma. Primary endpoint: Proportion of patients with sustained resolution of heartburn at the end of Week 1. Started Dec 2023; status: completed.
02
Drugs
rabeprazoleomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on PACTR202305577953836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202305577953836.